Working... Menu
Trial record 1 of 1 for:    A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in
Previous Study | Return to List | Next Study

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03836352
Recruitment Status : Recruiting
First Posted : February 11, 2019
Last Update Posted : August 20, 2019
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
ImmunoVaccine Technologies, Inc. (IMV Inc.)

Brief Summary:
This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide with pembrolizumab in subjects with selected advanced and recurrent solid tumours.

Condition or disease Intervention/treatment Phase
Ovarian Cancer Hepatocellular Carcinoma Non-small Cell Lung Cancer Bladder Cancer Microsatellite Instability-High Other: DPX-Survivac Drug: Cyclophosphamide Drug: Pembrolizumab Phase 2

Detailed Description:

This study is a Phase 2 with safety lead-in study to assess the safety and efficacy of DPX-Survivac, low dose cyclophosphamide, and pembrolizumab combination therapy in subjects with selected advanced and recurrent solid tumours. Two ovarian cancer arms will be recruited and randomized in this study, one with and one without cyclophosphamide. All other cohorts will be single arm, receiving treatment with the triple combination.

Up to 20 subjects, from any cohort, will be enrolled to assess the safety of study treatments before the study moves to the expansion phase. Once the safety lead-in is completed, the five cohorts will be expanded to recruit additional subjects following a Simon two stage design. Enrollment in the ovarian cancer cohort will be randomized 1:1 into two arms.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 184 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.
Actual Study Start Date : December 21, 2018
Estimated Primary Completion Date : December 31, 2022
Estimated Study Completion Date : December 31, 2022

Arm Intervention/treatment
Experimental: Arm 1 (All cohorts)
DPX-Survivac, Cyclophosphamide, Pembrolizumab
Other: DPX-Survivac
SubQ injection (q9w)

Drug: Cyclophosphamide

Drug: Pembrolizumab
IV Infusion (q3w)
Other Name: MK-3475

Experimental: Arm 2 (Ovarian cohort only)
DPX-Survivac, Pembrolizumab
Other: DPX-Survivac
SubQ injection (q9w)

Drug: Pembrolizumab
IV Infusion (q3w)
Other Name: MK-3475

Primary Outcome Measures :
  1. Efficacy as measured by objective response rate [ Time Frame: Approximately 24 months ]
    Centrally evaluated using RECIST v1.1

  2. Safety as measured by the rate of adverse events [ Time Frame: Approximately 24 months ]
    Using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0

Secondary Outcome Measures :
  1. Objective response rate [ Time Frame: Approximately 24 months ]
    Centrally evaluated using iRECIST

  2. Duration of response [ Time Frame: Approximately 24 months ]
  3. Disease control rate [ Time Frame: Approximately 24 months ]
  4. Progression Free Survival [ Time Frame: Approximately 24 months ]
  5. Overall survival [ Time Frame: Approximately 24 months ]

Other Outcome Measures:
  1. Cell mediated immunology [ Time Frame: Approximately 24 months ]
    As measured by antigen specific immune response in peripheral blood

  2. Changes in immune cell infiltration [ Time Frame: Approximately 24 months ]
    As measured by multiplex immunohistochemistry

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Subjects with advanced or metastatic solid tumours who have completed treatment with first line therapy:

    1. Epithelial ovarian, fallopian tube, or peritoneal cancer
    2. Hepatocellular carcinoma
    3. Non-small cell lung cancer
    4. Urothelial cancer
    5. Microsatellite instability high solid tumours, other than the above indications
  • Radiologic and/or biochemical evidence of disease progression
  • Completion of pre-treatment tumour biopsy
  • Subjects with HCC, NSCLC, BlCa, or MSI-H subjects other than those with gastric or colorectal cancer must have evidence of survivin expression in their pre-treatment biopsy sample
  • Must have measurable disease by RECIST v1.1
  • Ambulatory with an ECOG 0-1
  • Life expectancy ≥ 6 months
  • Meet protocol-specified laboratory requirements

Key Exclusion Criteria:

  • Chemotherapy or immunotherapy within treatment within 28 days of start of study treatment
  • Radiotherapy within treatment within 2 weeks of start of study treatment
  • Prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T cell receptor where subject was discontinued from that treatment due to a Grade 3 or higher immune-related toxicity
  • For NSCLC subjects: Known EGFR mutations or ALK rearrangements
  • Prior receipt of survivin-based vaccine(s) and/or immunotherapies
  • Concurrent second malignancy other than non-melanoma skin cancer, cervical carcinoma in situ, or controlled bladder cancer
  • Clinical ascites or pleural fluid that cannot be managed
  • Malignant bowel obstruction or recent history of bowel obstruction
  • For OvCa, subjects with any single lesion greater than 5 cm
  • Autoimmune disease requiring treatment within the last two years (except replacement therapy)
  • Recent history of thyroiditis
  • Any history of (non-infectious) pneumonitis that required steroid therapy or current pneumonitis
  • Presence of a serious acute or chronic infection
  • Active CNS metastases and/or carcinomatous meningitis
  • GI condition that might limit absorption of oral agents
  • Allogenic tissue/solid organ transplant
  • Other serious intercurrent chronic or acute illness, including myocardial infarction or cerebrovascular event within 6 months
  • Ongoing treatment with steroid therapy or other immunosuppressive
  • Receipt of live attenuated vaccines
  • Acute or chronic skin and/or microvascular disorders
  • Edema or lymphedema in the lower limbs > grade 2
  • Severe hypersensitivity (≥ Grade 3) to pembrolizumab

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03836352

Layout table for location information
United States, Florida
Comprehensive Hematology and Oncology Recruiting
Saint Petersburg, Florida, United States, 33709
Contact: Gouri Deshpande    727-344-6569 ext 1025   
Contact: Gina Askar    (727)344-6569 ext 1025   
Principal Investigator: Pratibha Desai, MD         
United States, Louisiana
Ochsner Cancer Institute Not yet recruiting
New Orleans, Louisiana, United States, 70121
Contact: Amanda Woolery   
Principal Investigator: Marc Matrana, MD         
United States, New York
NYU Winthrop Hospital Recruiting
Mineola, New York, United States, 11501
Contact: Jennifer Himmel    516-663-1216   
Principal Investigator: Eva Chalas, MD         
United States, Texas
Mary Crowley Cancer Research Center Recruiting
Dallas, Texas, United States, 75230
Contact: Referral Office    972-566-3000   
Principal Investigator: James Strauss, MD         
MD Anderson Recruiting
Houston, Texas, United States, 77030
Contact: Khanh Tran    713-794-5177   
Principal Investigator: Siqing Fu, MD         
Canada, Ontario
William Osler Health System Recruiting
Brampton, Ontario, Canada, L6R3J7
Contact: Dr Henry Conter, MD    905-494-2120 ext 57264   
Principal Investigator: Henry Conter, MD         
Juravinski Cancer Center Recruiting
Hamilton, Ontario, Canada, L8V 5C2
Contact: Yvonne Kinrade    905-387-9711 ext 64402   
Principal Investigator: Hal Hirte, MD         
Sunnybrook Research Institute Recruiting
Toronto, Ontario, Canada
Contact: Ilda Carvalhana    (416) 480-5000 ext 87435   
Principal Investigator: Mark Doherty, MD         
Canada, Quebec
McGill University Health Center Recruiting
Montreal, Quebec, Canada, H4A 3J1
Contact: Taylor Grant    514-934-1934 ext 23982    Taylor.Grant@MUHC.MCGILL.CA   
Principal Investigator: Lucy Gilbert, MD         
CHU de Québec-Université Laval Recruiting
Québec, Quebec, Canada, G1R 2J6
Contact: Maryse Gingras    418-691-5781   
Principal Investigator: Vincent Castonguay, MD         
Sponsors and Collaborators
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Merck Sharp & Dohme Corp.

Layout table for additonal information
Responsible Party: ImmunoVaccine Technologies, Inc. (IMV Inc.) Identifier: NCT03836352     History of Changes
Other Study ID Numbers: P1719-SUR-Z11
Keynote 903 ( Other Identifier: Sponsor )
First Posted: February 11, 2019    Key Record Dates
Last Update Posted: August 20, 2019
Last Verified: August 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by ImmunoVaccine Technologies, Inc. (IMV Inc.):
T cell activation
Hepatocellular Carcinoma
Non-small Cell Lung
Microsatellite Instability-High

Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Hepatocellular
Urinary Bladder Neoplasms
Microsatellite Instability
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Urogenital Neoplasms
Liver Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Liver Diseases
Urologic Neoplasms
Urinary Bladder Diseases
Urologic Diseases
Genomic Instability
Pathologic Processes
Immunosuppressive Agents